{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"50"}],"units":"Participants"}],"description":"ECG parameters included heart rate (HR), PR interval, QT interval, QTc corrected using Fridericia's formula (QTcF) and QRS complex. HR: RR (interval between 2 successive R waves on ECG) decrease \\>25% and to a VR (interval between QRS wave and T wave on ECG) \\>100, RR increase \\>25% and to a VR \\<50; PR interval: baseline less than or equal to (\\<=) 200 and % change \\>= 50%; QT interval: \\>450, \\>480, \\>500, increase from baseline \\>30, increase from baseline \\>60; QTcF: 470 \\< value \\<= 480, 480 \\< value \\<= 500, value \\> 500, 30 \\< change \\<= 60 and change \\>60; QRS complex: value \\>= 140, % change \\>=50%. Clinically significant values were determined by the investigator.","groups":[{"description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses).","id":"OG000","title":"Part A: Placebo"},{"description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG001","title":"Part A: Ponsegromab 100 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG002","title":"Part A: Ponsegromab 200 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG003","title":"Part A: Ponsegromab 400 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"Day 1 up to Week 12","title":"Part A: Number of Participants With Clinically Significant Echocardiogram (ECG) Abnormalities","type":"SECONDARY","unitOfMeasure":"Participants"}